{"entity":{"edinet_code":"E00942","sec_code":"4527","name_ja":"ロート製薬株式会社","name_en":"ROHTO PHARMACEUTICAL CO.,LTD.","industry":"医薬品","industry_en":"Pharmaceutical"},"names_note":"English company names are as filed: each company's own annual report states its English name on the cover page. For a company that files no annual report, EDINET's filer registry is used instead. The as-filed Japanese name is always returned alongside.","filing":{"doc_id":"S100YE5N","filer_name":"ロート製薬株式会社","filer_name_en":"ROHTO PHARMACEUTICAL CO.,LTD.","period_end":"2026-03-31","filed_date":"2026-06-19","sha256":"e621845834c19e8345d9a6ae3e02493a51d502d0fdeb7e18dce4c7239b0247a3","status":"clean"},"basis":{"measurement":"carrying_amount","entity_scope":"parent_only","share_scope":"both","trust_included":"unknown","as_of":"2026-03-31","period_type":"annual","labels":{"measurement":"Balance-sheet carrying amount. Under Japanese GAAP listed equities are carried at market with the valuation difference in other comprehensive income, so carrying amount and acquisition cost diverge enormously on positions bought decades ago.","entity_scope":"The reporting company itself (提出会社) — the holding company, excluding the group holders it names separately.","share_scope":"Listed and unlisted shares together.","trust_included":"The filing does not state whether retirement-benefit-trust shares are included. Never guessed — shares contributed to such a trust leave the holder's balance sheet while the settlor normally keeps the right to instruct the vote.","period_type":"From an annual securities report (有価証券報告書). The policy shareholding table appears only in the annual report."},"not_comparable":"Figures are balance-sheet CARRYING AMOUNT at fiscal year end, from the annual securities report. They are NOT comparable with the acquisition-cost or book-value-reduction figures quoted in press coverage and IR presentations, and NOT comparable with interim (half-year) figures, which this product does not hold. Always state the basis with the number, and use check_claim before setting one of our figures against a published one."},"basis_note":"The basis every yen figure on this response is on. entity_scope is read from the filing's own disclosing entities, not assumed: scale_entities and flows each carry their own entity_scope and share_scope, and a figure quoted for one entity is not the group figure.","holdings":[{"holder_table":"reporting","held_name_raw":"(株)三菱ＵＦＪフィナンシャル・グループ","held_name_en":"Mitsubishi UFJ Financial Group, Inc.","held_sec_code":"8306","match_status":"matched","shares":1380000,"book_value_yen":3588000000,"prior_shares":1380000,"prior_book_value_yen":2775000000,"purpose_ja":"同社とは、資金調達や決済を含む金融取引を通じて継続的な関係が形成されており、当社グループの運営基盤の安定に寄与しています。また、国内外のネットワークを通じた情報提供や経営全般に関する提案等も受けており、中長期的な価値向上に向けた連携が進んでいます。さらに、同グループ傘下の三菱ＵＦＪ信託銀行(株)とは証券代行業務に関する取引を通じて実務面での協働もあります。こうした多面的な関係性を踏まえ、同社株式を保有しております。","reciprocal":"無","pct_outstanding":0.01221633718178407,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":1.1206406516456677,"pct_of_holder_assets":0.7386196376481923,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":320174000000,"holder_total_assets_yen":485771000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"大木ヘルスケアホールディングス(株)","held_name_en":"OHKI HEALTHCARE HOLDINGS CO.,LTD.","held_sec_code":"3417","match_status":"matched","shares":1759530,"book_value_yen":2341000000,"prior_shares":1759527,"prior_book_value_yen":1409000000,"purpose_ja":"同社は、主要販売代理店としており、流通管理の適正化（過剰流通・不正転売防止等）を含めた取引関係の維持・強化を通じて、中長期的な企業価値の向上を図ることを目的として、同社株式を保有しております。なお、株式数は取引先持株会における配当金再投資による買付により増加しています。 ","reciprocal":"無","pct_outstanding":12.901671799384074,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.7311649290698183,"pct_of_holder_assets":0.48191431765173304,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":320174000000,"holder_total_assets_yen":485771000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"(株)マツキヨココカラ＆カンパニー","held_name_en":"MatsukiyoCocokara&Co.","held_sec_code":"3088","match_status":"matched","shares":665700,"book_value_yen":1681000000,"prior_shares":665700,"prior_book_value_yen":1557000000,"purpose_ja":"同社とは、当社ブランド（「リセ」「メラノCC」「スキンアクア」「モコラ」等）において、両社の強みを活かした商品を限定品等として展開し、新市場の創出及び売上拡大を図ることを目的として、同社株式を保有しております。","reciprocal":"有","pct_outstanding":0.16701446502823228,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.5250270165597456,"pct_of_holder_assets":0.3460478291211291,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":320174000000,"holder_total_assets_yen":485771000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"わかもと製薬(株)","held_name_en":"WAKAMOTO PHARMACEUTICAL CO.,LTD.","held_sec_code":"4512","match_status":"matched","shares":3971900,"book_value_yen":1394000000,"prior_shares":3971900,"prior_book_value_yen":1259000000,"purpose_ja":"同社とは、医療用眼科医薬品の開発推進を目的として、共同開発・販売及び乳酸菌を活用した製品開発等に関する包括的業務提携を締結しております。これらの関係を通じたシナジー創出により、中長期的な企業価値の向上を図ることを目的として、同社株式を保有しております。","reciprocal":"有","pct_outstanding":11.444443564031214,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.435388257634911,"pct_of_holder_assets":0.2869664924419119,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":320174000000,"holder_total_assets_yen":485771000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"(株)三井住友フィナンシャルグループ","held_name_en":"Sumitomo Mitsui Financial Group, Inc.","held_sec_code":"8316","match_status":"matched","shares":213300,"book_value_yen":1067000000,"prior_shares":213300,"prior_book_value_yen":809000000,"purpose_ja":"同社とは、資金調達や決済を含む金融取引を通じて継続的な関係が形成されており、当社グループの運営基盤の安定に寄与しています。また、国内外のネットワークを通じた情報提供や経営全般に関する提案等も受けており、中長期的な価値向上に向けた連携が進んでいます。さらに、同グループ傘下のＳＭＢＣ日興証券(株)とは社債発行に関する事務を通じて実務面での協働もあります。こうした多面的な関係性を踏まえ、同社株式を保有しております。","reciprocal":"無","pct_outstanding":0.005587514379794391,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.33325629189128414,"pct_of_holder_assets":0.21965082312447634,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":320174000000,"holder_total_assets_yen":485771000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"森下仁丹(株)","held_name_en":"MORISHITA JINTAN CO., LTD.","held_sec_code":"4524","match_status":"matched","shares":355000,"book_value_yen":789000000,"prior_shares":355000,"prior_book_value_yen":751000000,"purpose_ja":"同社とは、新製品開発及び国内外販売に関する業務・資本提携関係を構築しており、当社役員の経営参画も含め、両社の技術及び販売基盤の活用によるシナジー創出を目的として、同社株式を保有しております。","reciprocal":"有","pct_outstanding":8.661071533131649,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.24642850450067777,"pct_of_holder_assets":0.16242221128885834,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":320174000000,"holder_total_assets_yen":485771000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"(株)池田泉州ホールディングス","held_name_en":"Senshu Ikeda Holdings, Inc.","held_sec_code":"8714","match_status":"matched","shares":810670,"book_value_yen":696000000,"prior_shares":810670,"prior_book_value_yen":352000000,"purpose_ja":"同社とは、地域に根差した大手金融機関として、資金調達を中心とする金融取引を通じて継続的な関係が形成されており、主として大阪地域での情報の収集を図るため、定期的な情報交換や地域経済に関する連携も進められています。また、こうした取引基盤と協働体制を安定的に維持していく観点から、同社株式を保有しております。","reciprocal":"無","pct_outstanding":0.29114205287171574,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.2173817986469857,"pct_of_holder_assets":0.1432773879050005,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":320174000000,"holder_total_assets_yen":485771000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"明治ホールディングス(株)","held_name_en":"Meiji Holdings Co.,Ltd.","held_sec_code":"2269","match_status":"matched","shares":180400,"book_value_yen":696000000,"prior_shares":180400,"prior_book_value_yen":586000000,"purpose_ja":"同社とは、2021年より体外診断薬（コロナウイルス・インフルエンザウイルス）の流通・販売に関する連携を継続しており、今後の事業継続及び拡大を目的として、同社株式を保有しております。","reciprocal":"有","pct_outstanding":0.06654321989509483,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.2173817986469857,"pct_of_holder_assets":0.1432773879050005,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":320174000000,"holder_total_assets_yen":485771000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"(株)南都銀行","held_name_en":"The Nanto Bank，Ltd.","held_sec_code":"8367","match_status":"matched","shares":376000,"book_value_yen":529000000,"prior_shares":75200,"prior_book_value_yen":297000000,"purpose_ja":null,"reciprocal":"有","pct_outstanding":null,"pct_unavailable":"holding restated onto a share base the issuer has not filed yet","pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.16522266017852794,"pct_of_holder_assets":0.1088990491404386,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":320174000000,"holder_total_assets_yen":485771000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":5.0,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"養命酒製造(株)","held_name_en":"YOMEISHU SEIZO CO., LTD.","held_sec_code":"2540","match_status":"matched","shares":126500,"book_value_yen":511000000,"prior_shares":126500,"prior_book_value_yen":372000000,"purpose_ja":null,"reciprocal":"有","pct_outstanding":0.9085359284662621,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.1596007171100714,"pct_of_holder_assets":0.10519359945324032,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":320174000000,"holder_total_assets_yen":485771000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"(株)ユーグレナ","held_name_en":"Euglena Co.,Ltd.","held_sec_code":"2931","match_status":"matched","shares":1069500,"book_value_yen":428000000,"prior_shares":1069500,"prior_book_value_yen":541000000,"purpose_ja":"同社とは、資本業務提携関係を構築しており、ヘルスケア商品の企画・販売連携及び藻類由来原料の共同研究等を推進しております。これらは当社の事業戦略にも資するものであり、中長期的な企業価値の向上を目的として、同社株式を保有しております。","reciprocal":"無","pct_outstanding":0.783066378109696,"pct_unavailable":null,"pct_basis_period_end":"2025-12-31","pct_share_classes":1,"pct_of_holder_equity":0.1336773129610774,"pct_of_holder_assets":0.08810735922893709,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":320174000000,"holder_total_assets_yen":485771000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"(株)ファーマフーズ","held_name_en":"Pharma Foods International Co., Ltd.","held_sec_code":"2929","match_status":"matched","shares":600000,"book_value_yen":399000000,"prior_shares":600000,"prior_book_value_yen":535000000,"purpose_ja":"同社とは、機能性食品素材の開発力と当社の製造・販売基盤を組み合わせた資本業務提携関係を構築しております。当該提携を通じて、ヘルスケア及びスキンケア分野における共同開発並びに市場開拓を推進し、新たな付加価値の創出を図るとともに、同社製原料の当社製品への活用を進めております。これらを通じて中長期的な企業価値の向上に資するものと判断し、同社株式を保有しております。","reciprocal":"有","pct_outstanding":2.0658738301989437,"pct_unavailable":null,"pct_basis_period_end":"2026-07-31","pct_share_classes":1,"pct_of_holder_equity":0.124619738017453,"pct_of_holder_assets":0.08213746806622874,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":320174000000,"holder_total_assets_yen":485771000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"(株)日阪製作所","held_name_en":"HISAKA WORKS, LTD.","held_sec_code":"6247","match_status":"matched","shares":162600,"book_value_yen":249000000,"prior_shares":162600,"prior_book_value_yen":160000000,"purpose_ja":"同社は、医薬品製造プロセス機器を提供する企業であり、当社は設備分野において取引関係を有しております。当該関係の維持・強化により、安定的な生産体制の確保及び製造技術の高度化を図ることを目的として、同社株式を保有しております。","reciprocal":"有","pct_outstanding":0.6183920285996806,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.07777021244698196,"pct_of_holder_assets":0.051258720672909666,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":320174000000,"holder_total_assets_yen":485771000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"堺化学工業(株)","held_name_en":"SAKAI CHEMICAL INDUSTRY CO., LTD.","held_sec_code":"4078","match_status":"matched","shares":70100,"book_value_yen":242000000,"prior_shares":70100,"prior_book_value_yen":189000000,"purpose_ja":"同社は、化粧品・医薬品用途の無機材料及び機能性材料を開発・供給する企業であり、当社は原材料分野において取引関係を有しております。当該関係の維持・強化により、高品質原材料の安定調達及び製品競争力の向上を図ることを目的として、同社株式を保有しております。","reciprocal":"有","pct_outstanding":0.457834787606458,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.0755839012536933,"pct_of_holder_assets":0.04981771246122144,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":320174000000,"holder_total_assets_yen":485771000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"三洋化成工業(株)","held_name_en":"SANYO CHEMICAL INDUSTRIES, LTD.","held_sec_code":"4471","match_status":"matched","shares":38400,"book_value_yen":190000000,"prior_shares":38400,"prior_book_value_yen":149000000,"purpose_ja":"同社とは、高機能素材技術と当社の医薬品・化粧品開発力を組み合わせた資本業務提携関係を構築しております。共同開発及び新規事業創出を推進し、事業シナジーの創出を図ることで、中長期的な企業価値の向上に資するものと判断し、同社株式を保有しております。","reciprocal":"有","pct_outstanding":0.17238707434533765,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.05934273238926334,"pct_of_holder_assets":0.039113080031537496,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":320174000000,"holder_total_assets_yen":485771000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"(株)坪田ラボ","held_name_en":"Tsubota Laboratory Incorporated","held_sec_code":"4890","match_status":"matched","shares":640000,"book_value_yen":188000000,"prior_shares":640000,"prior_book_value_yen":252000000,"purpose_ja":"同社とは、眼科領域における医療用医薬品の研究開発に関する共同研究関係を構築しており、臨床試験の推進及び製品化を進めております。先端研究の社会実装及び医薬品事業の強化を通じて、中長期的な企業価値の向上に資するものと判断し、同社株式を保有しております。","reciprocal":"無","pct_outstanding":2.4811683201327424,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.05871807204832372,"pct_of_holder_assets":0.03870136339962657,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":320174000000,"holder_total_assets_yen":485771000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"(株)メディパルホールディングス","held_name_en":"MEDIPAL HOLDINGS CORPORATION","held_sec_code":"7459","match_status":"matched","shares":33000,"book_value_yen":96000000,"prior_shares":33000,"prior_book_value_yen":77000000,"purpose_ja":"同社は、医薬品等の卸売事業を営んでおり、当社製品の流通・販売において重要な取引関係を有しております。特に再生医療関連製品の流通及び医療機関向け情報提供において連携しており、当該関係の維持・強化を通じて安定供給及び販売機会の拡大を図ることを目的として、同社株式を保有しております。","reciprocal":"有","pct_outstanding":0.016121259856721474,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.029983696365101477,"pct_of_holder_assets":0.019762398331724208,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":320174000000,"holder_total_assets_yen":485771000000,"implausible":false,"reciprocal_held_both_ways":true,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"VIZIONFOCUS INC.","held_name_en":null,"held_sec_code":null,"match_status":"foreign","shares":100000,"book_value_yen":89000000,"prior_shares":100000,"prior_book_value_yen":90000000,"purpose_ja":"同社は、ソフトコンタクトレンズの開発・製造を行う企業であり、当社の関連事業における協業可能性を有しております。当該関係の維持・強化により、供給体制の安定化及び商品競争力の向上を図ることを目的として、同社株式を保有しております。","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":null,"pct_share_classes":null,"pct_of_holder_equity":0.027797385171812825,"pct_of_holder_assets":0.018321390120035985,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":320174000000,"holder_total_assets_yen":485771000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"スギホールディングス(株)","held_name_en":"SUGI HOLDINGS CO.,LTD.","held_sec_code":"7649","match_status":"matched","shares":24000,"book_value_yen":83000000,"prior_shares":24000,"prior_book_value_yen":67000000,"purpose_ja":"同社とは、同社専売の目薬や洗眼薬の提供を行うとともにアイケアの啓蒙活動を推進しております。当該連携の継続・発展を目的として、同社株式を保有しております。","reciprocal":"無","pct_outstanding":0.013261653067044054,"pct_unavailable":null,"pct_basis_period_end":"2026-02-28","pct_share_classes":1,"pct_of_holder_equity":0.025923404148993984,"pct_of_holder_assets":0.01708624022430322,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":320174000000,"holder_total_assets_yen":485771000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"(株)りそなホールディングス","held_name_en":"Resona Holdings, Inc.","held_sec_code":"8308","match_status":"matched","shares":48000,"book_value_yen":82000000,"prior_shares":48000,"prior_book_value_yen":61000000,"purpose_ja":"同社とは、資金調達を中心とする金融取引を通じて継続的な関係が形成されており、当社グループの運営基盤の安定に寄与しています。また、国内のネットワークを通じた情報提供を受けており、中長期的な価値向上に向けた連携が進んでいます。さらに、同グループ傘下の(株)りそな銀行とは年金資産の一部の委託運用に関する事務を通じて実務面での協働もあります。こうした多面的な関係性を踏まえ、同社株式を保有しております。","reciprocal":"無","pct_outstanding":0.0021219775788082515,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.025611073978524176,"pct_of_holder_assets":0.01688038190834776,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":320174000000,"holder_total_assets_yen":485771000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"(株)クラダシ","held_name_en":"KURADASHI.Co.,Ltd.","held_sec_code":"5884","match_status":"matched","shares":151286,"book_value_yen":70000000,"prior_shares":151286,"prior_book_value_yen":47000000,"purpose_ja":"同社は、フードロス削減に資する流通モデルを展開しており、当社製品の販売機会拡大及びサステナビリティ推進において連携関係を有しております。当該関係の維持・強化により、新たな販売チャネルの開拓及び環境負荷低減を図ることを目的として、同社株式を保有しております。 ","reciprocal":"無","pct_outstanding":1.2461514409331333,"pct_unavailable":null,"pct_basis_period_end":"2026-06-30","pct_share_classes":1,"pct_of_holder_equity":0.02186311193288649,"pct_of_holder_assets":0.014410082116882234,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":320174000000,"holder_total_assets_yen":485771000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"Waldencast Acquisition Corp.","held_name_en":null,"held_sec_code":null,"match_status":"foreign","shares":250000,"book_value_yen":37000000,"prior_shares":250000,"prior_book_value_yen":112000000,"purpose_ja":"同社グループとは、「OBAGI」ブランドに関する長年の協業関係を有しており、ブランド価値の維持・向上に取り組んでおります。当該関係の維持・強化を通じて、スキンケア事業の基盤強化及び事業拡大を図ることを目的として、同社株式を保有しております。","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":null,"pct_share_classes":null,"pct_of_holder_equity":0.01155621630738286,"pct_of_holder_assets":0.007616757690352039,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":320174000000,"holder_total_assets_yen":485771000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"(株)フツパー","held_name_en":"Hutzper Inc.","held_sec_code":"478A","match_status":"matched","shares":50000,"book_value_yen":34000000,"prior_shares":null,"prior_book_value_yen":null,"purpose_ja":"同社とは、資本業務提携関係を構築し、共同で研究開発プロセスの自動化及び効率化に関する事業を推進しております。標的探索から実験実行までを自律的に支援する統合型AIエージェント「リアラボAI」を共同で開発しており、これらの取り組みは当社の事業戦略に資するものであります。このため、中長期的な企業価値の向上を目的として、同社株式を保有しております。株式の増加理由は前述の株式上場に伴う増加となっております。","reciprocal":"無","pct_outstanding":0.49800796812749004,"pct_unavailable":null,"pct_basis_period_end":"2025-12-31","pct_share_classes":1,"pct_of_holder_equity":0.01061922579597344,"pct_of_holder_assets":0.006999182742485657,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":320174000000,"holder_total_assets_yen":485771000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":["2"],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"iXensor Co.,Ltd.","held_name_en":null,"held_sec_code":null,"match_status":"foreign","shares":500000,"book_value_yen":15000000,"prior_shares":500000,"prior_book_value_yen":13000000,"purpose_ja":"同社とは、検査薬・診断分野における出資関係を構築しており、スマートフォンベースの診断技術等に関する協業を推進しております。当該関係の維持・強化を通じて、検査薬事業の拡大及び新規診断ビジネスの創出を図ることを目的として、同社株式を保有しております。","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":null,"pct_share_classes":null,"pct_of_holder_equity":0.0046849525570471055,"pct_of_holder_assets":0.0030878747393319073,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":320174000000,"holder_total_assets_yen":485771000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false},{"holder_table":"reporting","held_name_raw":"(株)ツルハホールディングス","held_name_en":"TSURUHA HOLDINGS INC.","held_sec_code":"3391","match_status":"matched","shares":4000,"book_value_yen":9000000,"prior_shares":4000,"prior_book_value_yen":8000000,"purpose_ja":"同社とは、OTC医薬品及び化粧品領域において、「アルガード」及び「リスタ」等、Well-beingの向上に資する商品を展開しており、特に「リスタ」については、トータルスキンケアブランドとしてラインアップの拡充を進めております。今後の販売強化及び取引関係の維持・強化を目的として、同社株式を保有しております。なお、ウエルシアホールディングス(株)は、(株)ツルハホールディングスとの経営統合に伴い、銘柄が変更となっております。","reciprocal":"無","pct_outstanding":0.0008805093940556679,"pct_unavailable":null,"pct_basis_period_end":"2026-02-28","pct_share_classes":1,"pct_of_holder_equity":0.0028109715342282634,"pct_of_holder_assets":0.0018527248435991444,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":320174000000,"holder_total_assets_yen":485771000000,"implausible":false,"reciprocal_held_both_ways":false,"corporate_actions":[],"note_refs":[],"share_ratio":null,"reclassified_to_pure":false}],"holders":[{"holder_name":"株式会社三菱ＵＦＪフィナンシャル・グループ","holder_name_en":"Mitsubishi UFJ Financial Group, Inc.","holder_sec_code":"8306","doc_id":"S100YJQO","period_end":"2026-03-31","holder_table":"largest","shares":7601140,"book_value_yen":18299000000,"prior_shares":7601140,"prior_book_value_yen":16999000000,"purpose_ja":"発行会社グループとの、主に金融取引(預金・貸出・為替等)における総合的な取引関係維持・拡大のために保有","reciprocal":"有","pct_outstanding":3.3638675063331904,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.07706739747959834,"pct_of_holder_assets":0.004238513512568231,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":23744152000000,"holder_total_assets_yen":431731548000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"株式会社　百五銀行","holder_name_en":"The Hyakugo Bank, Ltd.","holder_sec_code":"8368","doc_id":"S100YBNQ","period_end":"2026-03-31","holder_table":"reporting","shares":2000000,"book_value_yen":4815000000,"prior_shares":2000000,"prior_book_value_yen":4473000000,"purpose_ja":"当行営業エリア内に工場を有するなど、保有に関する経済合理性を有し、業界内の有力企業である同社との協力関係の維持・向上を通じた、当行の中長期的な企業価値向上","reciprocal":"無","pct_outstanding":0.8850955268112916,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.9319655472757186,"pct_of_holder_assets":0.06310115646138151,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":516650000000,"holder_total_assets_yen":7630605000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"株式会社池田泉州ホールディングス","holder_name_en":"Senshu Ikeda Holdings, Inc.","holder_sec_code":"8714","doc_id":"S100YAWY","period_end":"2026-03-31","holder_table":"largest","shares":1496328,"book_value_yen":3602000000,"prior_shares":1496328,"prior_book_value_yen":3346000000,"purpose_ja":null,"reciprocal":"有","pct_outstanding":0.6621966097212432,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":1.4185346796679321,"pct_of_holder_assets":0.05460901115391327,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":253924000000,"holder_total_assets_yen":6595981000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"株式会社電通グループ","holder_name_en":"DENTSU GROUP INC.","holder_sec_code":"4324","doc_id":"S100Y36E","period_end":"2025-12-31","holder_table":"reporting","shares":1040000,"book_value_yen":2733000000,"prior_shares":1040000,"prior_book_value_yen":2992000000,"purpose_ja":"（注）１．２．","reciprocal":"無","pct_outstanding":0.4602496739418716,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.729093581682224,"pct_of_holder_assets":0.08522549205793836,"holder_equity_basis":"ifrs_consolidated_excl_nci","holder_equity_yen":374849000000,"holder_total_assets_yen":3206787000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"養命酒製造株式会社","holder_name_en":"YOMEISHU SEIZO CO., LTD.","holder_sec_code":"2540","doc_id":"S100YK3W","period_end":"2026-03-31","holder_table":"reporting","shares":884000,"book_value_yen":2128230000,"prior_shares":884000,"prior_book_value_yen":1977066000,"purpose_ja":"医薬品分野における取引・協力関係の構築による企業価値向上を図るため株式を保有しております。","reciprocal":"有","pct_outstanding":0.3912122228505909,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":4.592083934567718,"pct_of_holder_assets":3.9378206129846887,"holder_equity_basis":"parent_only","holder_equity_yen":46345625000,"holder_total_assets_yen":54045885000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"森下仁丹株式会社","holder_name_en":"MORISHITA JINTAN CO., LTD.","holder_sec_code":"4524","doc_id":"S100YE3I","period_end":"2026-03-31","holder_table":"reporting","shares":820000,"book_value_yen":1974000000,"prior_shares":820000,"prior_book_value_yen":1833000000,"purpose_ja":"〔保有目的〕資本業務提携による。評価損益、受取配当金等から検証。","reciprocal":"有","pct_outstanding":0.36288916599262955,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":15.21152808815597,"pct_of_holder_assets":10.599795951243086,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":12977000000,"holder_total_assets_yen":18623000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"株式会社　りそなホールディングス","holder_name_en":"Resona Holdings, Inc.","holder_sec_code":"8308","doc_id":"S100YDP3","period_end":"2026-03-31","holder_table":"largest","shares":797000,"book_value_yen":1918000000,"prior_shares":797000,"prior_book_value_yen":1782000000,"purpose_ja":"事業上の関係を総合的に勘案し、中長期的かつ安定的な取引関係の構築を図るため。","reciprocal":"有","pct_outstanding":0.3527105674342997,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.06549734442075658,"pct_of_holder_assets":0.002513830919470226,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":2928363000000,"holder_total_assets_yen":76297892000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"株式会社ＰＡＬＴＡＣ","holder_name_en":"ＰＡＬＴＡＣ　ＣＯＲＰＯＲＡＴＩＯＮ","holder_sec_code":"8283","doc_id":"S100YDG4","period_end":"2026-03-31","holder_table":"reporting","shares":663040,"book_value_yen":1596000000,"prior_shares":663040,"prior_book_value_yen":1482000000,"purpose_ja":"同社とは当社が取り扱う商品の仕入取引があり、中長期視点で取引深耕・拡大を目的に株式を保有しております。また、同社とは相応の取引金額を有しております。","reciprocal":"無","pct_outstanding":0.29342686904847937,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.5289356991827346,"pct_of_holder_assets":0.29990360241350994,"holder_equity_basis":"parent_only","holder_equity_yen":301738000000,"holder_total_assets_yen":532171000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"株式会社メディパルホールディングス","holder_name_en":"MEDIPAL HOLDINGS CORPORATION","holder_sec_code":"7459","doc_id":"S100YI1C","period_end":"2026-03-31","holder_table":"second_largest","shares":663040,"book_value_yen":1596000000,"prior_shares":663040,"prior_book_value_yen":1482000000,"purpose_ja":"同社とは当社グループ会社が取り扱う商品の仕入取引があり、中長期視点で取引深耕・拡大を目的に株式を保有しております。また、同社とは相応の取引金額を有しております。定量的な保有効果については、（注）に記載しております。","reciprocal":"有","pct_outstanding":0.29342686904847937,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.2006540113829663,"pct_of_holder_assets":0.08303841515253366,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":795399000000,"holder_total_assets_yen":1922002000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"明治ホールディングス株式会社","holder_name_en":"Meiji Holdings Co.,Ltd.","holder_sec_code":"2269","doc_id":"S100YILP","period_end":"2026-03-31","holder_table":"reporting","shares":656200,"book_value_yen":1579000000,"prior_shares":656200,"prior_book_value_yen":1467000000,"purpose_ja":"医薬品セグメントにおける体外診断用医薬品の販売提携契約等があり、当社グループの事業上の関係強化のため保有しております。","reciprocal":"有","pct_outstanding":0.2903998423467848,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.1931375618920876,"pct_of_holder_assets":0.12514275705582445,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":817552000000,"holder_total_assets_yen":1261759000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"株式会社マツキヨココカラ＆カンパニー","holder_name_en":"MatsukiyoCocokara&Co.","holder_sec_code":"3088","doc_id":"S100YD1I","period_end":"2026-03-31","holder_table":"reporting","shares":466000,"book_value_yen":1121000000,"prior_shares":466000,"prior_book_value_yen":1042000000,"purpose_ja":"（保有目的）商品の安定供給（商品仕入）を通じた当社事業の円滑化のため保有（定量的な保有効果）（注）２","reciprocal":"有","pct_outstanding":0.20622725774703093,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.20589548003401592,"pct_of_holder_assets":0.14831357803530154,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":544451000000,"holder_total_assets_yen":755831000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"株式会社博報堂ＤＹホールディングス","holder_name_en":"HAKUHODO DY HOLDINGS INCORPORATED","holder_sec_code":"2433","doc_id":"S100YHXU","period_end":"2026-03-31","holder_table":"largest","shares":440000,"book_value_yen":1059000000,"prior_shares":440000,"prior_book_value_yen":984000000,"purpose_ja":"(保有目的)取引関係の維持強化のため(定量的な保有効果)※１","reciprocal":"無","pct_outstanding":0.19472101589848415,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.263095131622097,"pct_of_holder_assets":0.09795288641904966,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":402516000000,"holder_total_assets_yen":1081132000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"株式会社ファーマフーズ","holder_name_en":"Pharma Foods International Co., Ltd.","holder_sec_code":"2929","doc_id":"S100Z9MI","period_end":"2026-07-31","holder_table":"reporting","shares":406000,"book_value_yen":969000000,"prior_shares":406000,"prior_book_value_yen":882000000,"purpose_ja":"当社主力の機能性食品素材「ボーンペップ」の取引拡大及び同社との取引による当社製品の認知度及び信頼度の向上を目的に保有しております。また、ヘルス＆ビューティーケア及び食分野の研究開発に関するパートナー企業であり、相互のリソースを活用して企業価値向上を図るべく、資本業務提携契約を締結し、同社株式を保有しております。","reciprocal":"有","pct_outstanding":0.1796743919426922,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":7.359866322345435,"pct_of_holder_assets":2.7595044852627084,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":13166000000,"holder_total_assets_yen":35115000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"大木ヘルスケアホールディングス株式会社","holder_name_en":"OHKI HEALTHCARE HOLDINGS CO.,LTD.","holder_sec_code":"3417","doc_id":"S100YF0K","period_end":"2026-03-31","holder_table":"largest","shares":274714,"book_value_yen":661000000,"prior_shares":272447,"prior_book_value_yen":609000000,"purpose_ja":"・同社株式は、当社グループの事業活動の円滑化のため保有しております。・同社グループは、当社グループにおける主要な仕入先であり、当社の事業継続に不可欠な取引先であります。・当社グループは保有株式について、配当・取引額に加え、経営戦略上の重要性や事業上の関係等を総合的に判断し、保有の便益とリスクの見合いを勘案し保有しております。定量的な保有効果については、取引先との関係性を考慮し記載しませんが、上記方針に基づいて総合的に保有効果を判断しております。 ・2025年度は、新規商品・カテゴリーの導入等に伴う、より一層の取引関係や協力関係の強化を図るため、取引先持株会を通じて保有株式数が増加しております。","reciprocal":"有","pct_outstanding":0.12157406627621857,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":1.9346718960369957,"pct_of_holder_assets":0.44543880102161154,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":34166000000,"holder_total_assets_yen":148393000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"アルフレッサホールディングス株式会社","holder_name_en":"Alfresa Holdings Corporation","holder_sec_code":"2784","doc_id":"S100YH29","period_end":"2026-03-31","holder_table":"largest","shares":229400,"book_value_yen":552000000,"prior_shares":229400,"prior_book_value_yen":513000000,"purpose_ja":"・良好な取引関係の維持発展・当社グループの取引先 ・検証実施(注)１","reciprocal":"無","pct_outstanding":0.10152045692525515,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.10868216962687757,"pct_of_holder_assets":0.036628675475243795,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":507903000000,"holder_total_assets_yen":1507016000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"わかもと製薬株式会社","holder_name_en":"WAKAMOTO PHARMACEUTICAL CO.,LTD.","holder_sec_code":"4512","doc_id":"S100YDBU","period_end":"2026-03-31","holder_table":"reporting","shares":217500,"book_value_yen":523631000,"prior_shares":217500,"prior_book_value_yen":486438000,"purpose_ja":"包括的業務提携を締結しており、取引関係の維持・強化のため保有しております。","reciprocal":"有","pct_outstanding":0.09625413854072795,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":4.360473564695113,"pct_of_holder_assets":3.173596801426846,"holder_equity_basis":"parent_only","holder_equity_yen":12008581000,"holder_total_assets_yen":16499607000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"アステナホールディングス株式会社","holder_name_en":"Astena Holdings Co., Ltd.","holder_sec_code":"8095","doc_id":"S100XN2T","period_end":"2025-11-30","holder_table":"reporting","shares":150480,"book_value_yen":380000000,"prior_shares":150480,"prior_book_value_yen":446000000,"purpose_ja":"定量的な保有効果の記載は困難ですが、主にファインケミカル事業、ＨＢＣ・食品事業における取引先であり、良好な関係の維持、強化を図るために保有しております。信頼関係の構築・維持強化の必要性や事業上の取引状況等に基づく保有意義、同社との取引関係等による経済合理性について経営陣が定期的に検証・審議を行い、保有の合理性があると判断しております。","reciprocal":"無","pct_outstanding":0.06659458743728158,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":1.3870131766251779,"pct_of_holder_assets":0.5037048819607375,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":27397000000,"holder_total_assets_yen":75441000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"株式会社日阪製作所","holder_name_en":"HISAKA WORKS, LTD.","holder_sec_code":"6247","doc_id":"S100YJL5","period_end":"2026-03-31","holder_table":"reporting","shares":154800,"book_value_yen":372000000,"prior_shares":154800,"prior_book_value_yen":346000000,"purpose_ja":"取引関係の維持・発展のために保有しており、プロセスエンジニアリング事業にて取引を行っております。","reciprocal":"有","pct_outstanding":0.06850639377519396,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.5878634639696586,"pct_of_holder_assets":0.4477504152524012,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":63280000000,"holder_total_assets_yen":83082000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"堺化学工業株式会社","holder_name_en":"SAKAI CHEMICAL INDUSTRY CO., LTD.","holder_sec_code":"4078","doc_id":"S100YICQ","period_end":"2026-03-31","holder_table":"reporting","shares":132000,"book_value_yen":317000000,"prior_shares":132000,"prior_book_value_yen":295000000,"purpose_ja":"同社とは、化粧品材料等の販売先として取引を行っております。取引における売上高および利益において重要度が高く、同社との良好な関係の維持・強化が必要と考え、保有しております。","reciprocal":"有","pct_outstanding":0.05841630476954524,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.4016573115568339,"pct_of_holder_assets":0.27044089544089545,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":78923000000,"holder_total_assets_yen":117216000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"三洋化成工業株式会社","holder_name_en":"SANYO CHEMICAL INDUSTRIES, LTD.","holder_sec_code":"4471","doc_id":"S100YC0P","period_end":"2026-03-31","holder_table":"reporting","shares":123400,"book_value_yen":297000000,"prior_shares":123400,"prior_book_value_yen":276000000,"purpose_ja":"生活・健康産業関連分野における研究開発のパートナー企業であります。化粧品及びバイオ・メディカル事業における共同研究開発の促進を目的として資本業務提携契約を締結した事に伴い、同社株式を保有しております。","reciprocal":"有","pct_outstanding":0.05461039400425669,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.18270626737862644,"pct_of_holder_assets":0.15189795730491085,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":162556000000,"holder_total_assets_yen":195526000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"株式会社メディパルホールディングス","holder_name_en":"MEDIPAL HOLDINGS CORPORATION","holder_sec_code":"7459","doc_id":"S100YI1C","period_end":"2026-03-31","holder_table":"reporting","shares":49508,"book_value_yen":119000000,"prior_shares":49508,"prior_book_value_yen":110000000,"purpose_ja":"・当社グループの化粧品・日用品、一般用医薬品卸売事業の商品の仕入等における良好な取引関係の維持・強化のため、保有しております。・定量的な保有効果については、（注）１に記載しております。","reciprocal":"有","pct_outstanding":0.02190965467068671,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.014961044708379065,"pct_of_holder_assets":0.006191460778916983,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":795399000000,"holder_total_assets_yen":1922002000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"株式会社あらた","holder_name_en":"ARATA CORPORATION","holder_sec_code":"2733","doc_id":"S100YEVF","period_end":"2026-03-31","holder_table":"reporting","shares":11499,"book_value_yen":27000000,"prior_shares":11181,"prior_book_value_yen":25000000,"purpose_ja":"主に卸売事業における仕入先であり、長期的・安定的な取引関係の維持・強化を通じて、当社の中長期的な企業価値の向上に資すると判断し、保有しております。2025年度において、取引関係の一層の強化を目的として株式を追加取得しており、318株増加しております。","reciprocal":"無","pct_outstanding":0.005088856731401521,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.021745783734153767,"pct_of_holder_assets":0.007761296998965161,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":124162000000,"holder_total_assets_yen":347880000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"ＣＢグループマネジメント株式会社","holder_name_en":"CB GROUP MANAGEMENT Co., Ltd.","holder_sec_code":"9852","doc_id":"S100TS8T","period_end":"2024-03-31","holder_table":"reporting","shares":null,"book_value_yen":20000000,"prior_shares":null,"prior_book_value_yen":18000000,"purpose_ja":"（保有目的）同社より日用雑貨品を仕入れています。同社との取引関係の維持、強化のため同社株式を継続保有しています。（定量的な保有効果）（注）１（株式数が増加した理由）取引先持株会を通じた株式の取得","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2024-03-31","pct_share_classes":1,"pct_of_holder_equity":0.0810142990237777,"pct_of_holder_assets":0.03759327832183606,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":24687000000,"holder_total_assets_yen":53201000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"株式会社スズケン","holder_name_en":"SUZUKEN CO.,LTD.","holder_sec_code":"9987","doc_id":"S100YFRU","period_end":"2026-03-31","holder_table":"reporting","shares":4000,"book_value_yen":9000000,"prior_shares":4000,"prior_book_value_yen":8000000,"purpose_ja":"保有目的 　商品の安定仕入を目的とし、同社との良好な取引　関係の維持、強化定量的な保有効果　当社の資本コスト、投下資本（株価）、受取配当　金及び取引高を総合的に勘案し検証しております ","reciprocal":"有","pct_outstanding":0.001770191053622583,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.0021633991327173253,"pct_of_holder_assets":0.0007787043398058085,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":416012000000,"holder_total_assets_yen":1155766000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"久光製薬株式会社","holder_name_en":"HISAMITSU PHARMACEUTICAL CO.,INC.","holder_sec_code":"4530","doc_id":"S100VT69","period_end":"2025-02-28","holder_table":"reporting","shares":4000,"book_value_yen":8000000,"prior_shares":null,"prior_book_value_yen":null,"purpose_ja":"協力関係の構築により、企業価値向上を図るため。","reciprocal":"無","pct_outstanding":0.0017701902702288383,"pct_unavailable":null,"pct_basis_period_end":"2025-03-31","pct_share_classes":1,"pct_of_holder_equity":0.0028632067199461718,"pct_of_holder_assets":0.002331899215315914,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":279407000000,"holder_total_assets_yen":343068000000,"implausible":false,"reciprocal_held_both_ways":false},{"holder_name":"小林製薬株式会社","holder_name_en":"KOBAYASHI PHARMACEUTICAL CO.,LTD.","holder_sec_code":"4967","doc_id":"S100XSXS","period_end":"2025-12-31","holder_table":"reporting","shares":2000,"book_value_yen":5000000,"prior_shares":2000,"prior_book_value_yen":5000000,"purpose_ja":"株主総会出席のために保有しております。","reciprocal":"有","pct_outstanding":0.0008850955268112916,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":0.0023695784046102518,"pct_of_holder_assets":0.0018160092107987172,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":211008000000,"holder_total_assets_yen":275329000000,"implausible":false,"reciprocal_held_both_ways":true},{"holder_name":"高砂香料工業株式会社","holder_name_en":"TAKASAGO INTERNATIONAL CORPORATION","holder_sec_code":"4914","doc_id":"S100YGT4","period_end":"2026-03-31","holder_table":"reporting","shares":null,"book_value_yen":null,"prior_shares":44000,"prior_book_value_yen":98000000,"purpose_ja":"当事業年度に全て売却しており、当事業年度末におきまして保有しておりません。","reciprocal":"無","pct_outstanding":null,"pct_unavailable":null,"pct_basis_period_end":"2026-03-31","pct_share_classes":1,"pct_of_holder_equity":null,"pct_of_holder_assets":null,"holder_equity_basis":"jgaap_consolidated","holder_equity_yen":156051000000,"holder_total_assets_yen":271147000000,"implausible":false,"reciprocal_held_both_ways":false}],"reclassified":[{"holder_table":"reporting","direction":"to_policy","held_name_raw":"(株)ヤクルト本社","held_name_en":"YAKULT HONSHA CO.,LTD.","held_sec_code":"2267","match_status":"matched","shares":346600,"book_value_yen":921000000,"fy_of_change_ja":null,"reason_ja":null,"implausible":false},{"holder_table":"reporting","direction":"to_policy","held_name_raw":"(株)アシックス","held_name_en":"ASICS Corporation","held_sec_code":"7936","match_status":"matched","shares":190400,"book_value_yen":791000000,"fy_of_change_ja":null,"reason_ja":null,"implausible":false}],"reclassified_note":"As filed, from the annual report's 保有目的を変更した投資株式 table. direction=to_pure means the filer moved the holding from a policy shareholding to 純投資目的 (pure investment); the shares are not necessarily sold, and the position leaves the named policy table in the year of the change. direction=to_policy is the reverse. fy_of_change_ja is the fiscal year the filer states the change took effect, verbatim — some filers list more than one. A filing repeats these rows for several years after the change, so this is a standing disclosure, not a one-year event.","implausible_note":"A row is flagged implausible when its two filed numbers are mutually impossible — book value ÷ shares of ¥1,000,000 or more, which no listed Japanese share reaches. It is a filer tagging error (a value entered at the wrong scale, or a share count in thousands), not an extraction error: the values match the filing's XBRL exactly. Flagged rows are still returned, exactly as filed, but are excluded from the yen aggregates here and counted in excluded_positions / excluded_yen so the exclusion is visible.","notes":[{"holder_table":"reporting","note_no":"1","text_ja":"(注) １　取引金額等は秘密情報であり、定量的な保有効果の記載が困難なため、保有の合理性を検証した方法を記載しております。"},{"holder_table":"reporting","note_no":"2","text_ja":"２　「―」は、当該銘柄を保有していないことを示しております。なお、(株)フツパーに関しましては、当事業年度に株式上場をしているため、前事業年度においては記載しておりません。"}],"notes_note":"The filing's own numbered footnotes to the named policy table, verbatim. The XBRL numbers them (注)1, (注)2 … and gives no link back to a row, so a note is tied to a position only where it names that issuer.","flows":[{"holder_table":"reporting","share_class":"listed","issues_increased":2,"acquisition_cost_yen":30000000,"issues_decreased":null,"sale_proceeds_yen":null,"entity_scope":"parent_only","share_scope":"listed"},{"holder_table":"reporting","share_class":"unlisted","issues_increased":9,"acquisition_cost_yen":2661000000,"issues_decreased":3,"sale_proceeds_yen":5000000,"entity_scope":"parent_only","share_scope":"unlisted"}],"flows_note":"The filer's own tally, as filed, of how many issues increased or decreased during the year and the yen involved — acquisition cost for increases, sale proceeds for decreases. Read against the reclassification table this separates what was actually sold from what merely changed category. Counts are as filed and are not corrected for filer tagging errors.","no_reduction_measure":"This product holds sale proceeds (売却価額), as filed, for one fiscal year. It does NOT hold a book-value-reduction measure. The two are different measures and must never be presented as equivalent.","scale":{"policy_total_yen":25132000000,"listed_yen":15516000000,"unlisted_yen":9616000000,"listed_issues":25,"unlisted_issues":54,"equity_yen":320174000000,"equity_basis":"jgaap_consolidated","total_assets_yen":485771000000,"assets_basis":"jgaap_consolidated","pct_of_equity":7.84948184424719,"pct_of_assets":5.173631196592633,"equity_basis_label":"Consolidated net assets (Japanese GAAP)","assets_basis_label":"Consolidated net assets (Japanese GAAP)","equity_calc":"total policy shareholdings ÷ shareholders' equity × 100, both as filed in this annual securities report","assets_calc":"total policy shareholdings ÷ total assets × 100, both as filed in this annual securities report"},"scale_entities":[{"holder_table":"reporting","share_class":"listed","book_value_yen":15516000000,"issue_count":25,"holder_table_label":"The filer itself","entity_scope":"parent_only","share_scope":"listed"},{"holder_table":"reporting","share_class":"unlisted","book_value_yen":9616000000,"issue_count":54,"holder_table_label":"The filer itself","entity_scope":"parent_only","share_scope":"unlisted"}],"scale_history":[{"year":"2022","period_end":"2022-03-31","policy_total_yen":10823000000,"equity_yen":183832000000,"equity_basis":"jgaap_consolidated","pct_of_equity":5.887440706732233,"pct_of_assets":3.940981767998048},{"year":"2023","period_end":"2023-03-31","policy_total_yen":15243000000,"equity_yen":215078000000,"equity_basis":"jgaap_consolidated","pct_of_equity":7.0871962729800355,"pct_of_assets":4.922225415513584},{"year":"2024","period_end":"2024-03-31","policy_total_yen":19253000000,"equity_yen":247036000000,"equity_basis":"jgaap_consolidated","pct_of_equity":7.793600932657588,"pct_of_assets":5.561637899906117},{"year":"2025","period_end":"2025-03-31","policy_total_yen":19624000000,"equity_yen":271440000000,"equity_basis":"jgaap_consolidated","pct_of_equity":7.229590333038609,"pct_of_assets":4.651614814814815},{"year":"2026","period_end":"2026-03-31","policy_total_yen":25132000000,"equity_yen":320174000000,"equity_basis":"jgaap_consolidated","pct_of_equity":7.84948184424719,"pct_of_assets":5.173631196592633}],"scale_note":"The policy total is Official (as filed) — the filing's own total carrying amount for the whole policy bucket, listed and unlisted, summed across the entities the filing discloses. It is a floor: holdings at group companies the filing does not name are disclosed nowhere and are not included. The percentages are calculated, not filed, and carry their formula. equity_basis names which figure the denominator is, because filers report under Japanese, IFRS or US accounting standards and an adopter of the latter two stops tagging the Japanese consolidated figure — a parent-only denominator is a different measure and is labelled as one, never silently mixed with a group figure. Percentages are null where equity or total assets is missing or not positive; missing is never shown as zero.","scale_reference":"ISS's Japan proxy voting guidelines recommend a vote against the top executive at a company that allocates 20 percent or more of its net assets to cross-shareholdings, a policy effective from February 2022. ISS counts unilateral holdings, not only mutual ones.","ownership_calc":"shares held ÷ (issuer's issued shares − treasury shares) × 100, both as filed, the denominator taken from the issuer's own annual securities report nearest the holding's fiscal year end","ownership_note":"Derived, not filed. The denominator is the issuer's own reported issued shares less treasury shares, from its annual report nearest this holding's fiscal year end on either side — pct_basis_period_end gives that date, and it can fall after the holding's date where that report is the closer one. For a single-class listed stock this equals the stake's share of market capitalisation. It is null where the issuer files no annual report we hold; where the issuer's share count moves by half or more across the window, because a split or issue makes the share base indeterminate; and where the result would exceed 100%, which is a data fault rather than a stake. It is less exact where the issuer has more than one share class (pct_share_classes > 1), because treasury shares are reported across all classes.","holder_share_calc":"this position's book value ÷ the holder's shareholders' equity (or total assets) × 100, both as filed in the holder's own annual securities report","holder_share_note":"The mirror of pct_outstanding. That sizes a stake against the ISSUER — how much of the issuer this holder owns. pct_of_holder_equity and pct_of_holder_assets size the same position against the HOLDER: how much of its own capital is committed to this one name. Calculated, not filed. Null where the holder's filing gives no usable denominator, never zero. holder_equity_basis says which accounting figure the denominator is, and a parent_only basis is not comparable with a consolidated one. A position CAN legitimately exceed 100% of equity — a holder whose book equity is smaller than one long-held stake is a real and commercially interesting case, not an error — so no ceiling is imposed. Extreme values are worth checking against the filing: where the position's own two filed numbers are mutually impossible the row is marked `implausible`, but that test catches only scale errors visible per share, so it does not catch every bad figure. The book value and share count are returned alongside so the reader can check.","action_calc":"keyword match over the filing's own stated purpose and table footnotes: 株式分割、株式併合、株式交換、株式移転、会社分割、合併、持株会社、商号変更、公開買付、上場廃止","ratio_calc":"current shares ÷ prior shares where that ratio is an exact whole number (or its exact reciprocal) — the signature of a split or a consolidation rather than a trade","history":[{"year":"2019","period_end":"2019-03-31","named_holdings":22,"book_value_yen":9991000000},{"year":"2022","period_end":"2022-03-31","named_holdings":22,"book_value_yen":9545000000},{"year":"2023","period_end":"2023-03-31","named_holdings":24,"book_value_yen":12832000000},{"year":"2024","period_end":"2024-03-31","named_holdings":26,"book_value_yen":15187000000},{"year":"2025","period_end":"2025-03-31","named_holdings":24,"book_value_yen":12468000000},{"year":"2026","period_end":"2026-03-31","named_holdings":25,"book_value_yen":15503000000}],"history_note":"One point per annual report filed. Each year's book value is as filed; book values are fair-valued at period end, so a change reflects both trading and market moves.","provenance":{"trust":"official","note":"Figures exactly as filed in each company's 有価証券報告書 (annual securities report), EDINET. Raw filings archived with SHA-256; doc_id links to the source filing."}}